Drug Profile
Research programme: monoclonal antibody therapeutics - AVEO
Alternative Names: AV-232; AV-323; AV-325; AV-368; AV-369; AV-370; AV-371; AV-378Latest Information Update: 04 Dec 2023
Price :
$50
*
At a glance
- Originator St Vincents Hospital, Sydney
- Developer AVEO Oncology
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Hepatocyte growth factor inhibitors; Immunomodulators; Notch signalling pathway inhibitors; Proto-oncogene protein c-met inhibitors; RON protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cachexia; Pulmonary arterial hypertension
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2021 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)